But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... like asthma and pulmonary fibrosis just got easier if a new drug-carrying molecule is as sneaky as its inventors ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.